The Desk Summary
ARCHIMED to Acquire Esperion Therapeutics for Up to $1.1 Billion
Brief
ARCHIMED agreed to acquire Esperion Therapeutics for up to $1.1 billion in total equity value, including $3.16 per share in cash at closing and up to $100 million in contingent milestone payments tied to future net sales. The 58% premium to Esperion's April 30 close values the commercial-stage biopharma, which markets non-statin therapies NEXLETOL and NEXLIZET for cardiovascular disease. Debt financing is provided by Pharmakon Advisors, with the transaction expected to close in the third quarter of 2026.
ARCHIMED, a healthcare-focused investment firm, has agreed to acquire Esperion Therapeutics, a commercial-stage biopharmaceutical company, in a transaction valued at up to approximately $1.1 billion in total equity.
Esperion develops cardiometabolic and rare/orphan disease therapies, including NEXLETOL and NEXLIZET for lowering LDL-C, and its shareholders will receive $3.16 per share at closing plus contingent milestone payments of up to $100 million tied to future net sales.
The deal, expected to close in the t...
Deal details
- Buyer
- ARCHIMED
- Sponsor
- Needs Verification
- Target
- Esperion Therapeutics
- Platform
- ARCHIMED
- Deal type
- Add-on
- Announced
- May 1, 2026
- Status
- announced